Pierre Bédossa

70.2k total citations · 17 hit papers
514 papers, 38.5k citations indexed

About

Pierre Bédossa is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Pierre Bédossa has authored 514 papers receiving a total of 38.5k indexed citations (citations by other indexed papers that have themselves been cited), including 313 papers in Epidemiology, 211 papers in Hepatology and 109 papers in Surgery. Recurrent topics in Pierre Bédossa's work include Liver Disease Diagnosis and Treatment (264 papers), Hepatitis C virus research (105 papers) and Hepatitis B Virus Studies (65 papers). Pierre Bédossa is often cited by papers focused on Liver Disease Diagnosis and Treatment (264 papers), Hepatitis C virus research (105 papers) and Hepatitis B Virus Studies (65 papers). Pierre Bédossa collaborates with scholars based in France, United States and United Kingdom. Pierre Bédossa's co-authors include Thierry Poynard, Valérie Paradis, P Opolon, Delphine Dargère, Michel Vidaud, Patrick Marcellin, Karine Clément, Dominique Valla, Joan Tordjman and Jacques Belghiti and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Pierre Bédossa

500 papers receiving 37.6k citations

Hit Papers

An Algorithm for the Grading of Activity in Chronic Hepat... 1994 2026 2004 2015 1996 1997 2003 1994 2019 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. An Algorithm for the Grading of Activity in Chronic Hepatitis C
    1996 3.3k citations Pierre Bédossa et al. profile →
  2. Natural history of liver fibrosis progression in patients with chronic hepatitis C
    1997 2.4k citations Pierre Bédossa et al. profile →
  3. Sampling Variability of Liver Fibrosis in Chronic Hepatitis C
    2003 1.8k citations Pierre Bédossa, Valérie Paradis et al. profile →
  4. Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients With Chronic Hepatitis C
    1994 1.7k citations Pierre Bédossa profile →
  5. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
    2019 930 citations Peter Eddowes, M. Sasso et al. Gastroenterology profile →
  6. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients
    2012 632 citations Pierre Bédossa, Christine Poitou et al. profile →
  7. Fibrosis in Human Adipose Tissue: Composition, Distribution, and Link With Lipid Metabolism and Fat Mass Loss
    2010 447 citations Joan Tordjman, Danièle Lacasa et al. profile →
  8. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease
    2014 421 citations Pierre Bédossa profile →
  9. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
    2016 395 citations Divya P. Kumar, Pierre Bédossa et al. profile →
  10. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
    2013 380 citations Raluca Pais, Frédéric Charlotte et al. profile →
  11. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
    2023 271 citations Rohit Loomba, Arun J. Sanyal et al. New England Journal of Medicine profile →
  12. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
    2020 231 citations Romina Lomonaco, Eddison Godinez Leiva et al. profile →
  13. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
    2024 217 citations Arun J. Sanyal, Pierre Bédossa et al. New England Journal of Medicine profile →
  14. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort
    2021 172 citations Stephen A. Harrison, Valérie Paradis et al. profile →
  15. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
    2023 146 citations Stephen A. Harrison, Guy Neff et al. profile →
  16. Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study
    2023 88 citations Quentin M. Anstee, Pierre Bédossa et al. profile →
  17. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial
    2024 44 citations Rohit Loomba, Pierre Bédossa et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pierre Bédossa France 94 28.0k 22.2k 5.6k 4.8k 4.1k 514 38.5k
Zachary Goodman United States 88 33.3k 1.2× 31.0k 1.4× 4.5k 0.8× 3.0k 0.6× 2.9k 0.7× 299 42.1k
Massimo Pinzani Italy 89 17.0k 0.6× 15.8k 0.7× 5.6k 1.0× 5.2k 1.1× 2.4k 0.6× 330 26.9k
David E. Kleiner United States 100 32.1k 1.1× 17.6k 0.8× 7.3k 1.3× 8.0k 1.7× 10.5k 2.6× 515 50.7k
Michael Torbenson United States 66 12.7k 0.5× 9.2k 0.4× 4.0k 0.7× 5.8k 1.2× 3.0k 0.7× 297 22.7k
Valérie Paradis France 78 13.3k 0.5× 12.0k 0.5× 5.6k 1.0× 4.5k 0.9× 1.6k 0.4× 435 25.1k
Frank Tacke Germany 104 22.5k 0.8× 16.5k 0.7× 6.3k 1.1× 9.2k 1.9× 3.4k 0.8× 708 45.5k
Linda D. Ferrell United States 60 13.0k 0.5× 10.3k 0.5× 6.6k 1.2× 2.9k 0.6× 3.0k 0.7× 222 21.7k
Christian Trautwein Germany 102 15.3k 0.5× 12.9k 0.6× 5.2k 0.9× 9.7k 2.0× 1.6k 0.4× 709 36.2k
Alastair D. Burt United Kingdom 60 12.2k 0.4× 8.5k 0.4× 3.2k 0.6× 2.7k 0.6× 3.8k 0.9× 238 18.4k
Frédéric Charlotte France 66 12.2k 0.4× 9.1k 0.4× 2.3k 0.4× 1.6k 0.3× 2.6k 0.6× 282 19.8k

Countries citing papers authored by Pierre Bédossa

Since Specialization
Citations

This map shows the geographic impact of Pierre Bédossa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Bédossa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Bédossa more than expected).

Fields of papers citing papers by Pierre Bédossa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Bédossa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Bédossa. The network helps show where Pierre Bédossa may publish in the future.

Co-authorship network of co-authors of Pierre Bédossa

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Bédossa. A scholar is included among the top collaborators of Pierre Bédossa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Bédossa. Pierre Bédossa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sharma, Anu, Eddison Godinez Leiva, Srilaxmi Kalavalapalli, et al.. (2025). Improving MASLD Risk Stratification in Young Adults with Cardiometabolic Risk Factors and Insulin Resistance Assessment. Journal of the Endocrine Society. 10(1). bvaf209–bvaf209. 1 indexed citations
2.
Sanyal, Arun J., Pierre Bédossa, Mandy Fraessdorf, et al.. (2024). A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine. 391(4). 311–319. 217 indexed citations breakdown →
3.
Lassen, Pierre Bel, Judith Aron‐Wisnewsky, Laurent Genser, et al.. (2024). Metabolic and hepatic phenotypes in sarcopenic obesity and impact of bariatric surgery. Clinical Nutrition. 43(12). 254–264. 3 indexed citations
4.
Hvid, Henning, Sara Toftegaard Hjuler, Pierre Bédossa, et al.. (2024). Choline-deficient, high-fat diet-induced MASH in Göttingen Minipigs: characterization and effects of a chow reversal period. American Journal of Physiology-Gastrointestinal and Liver Physiology. 327(4). G571–G585. 2 indexed citations
5.
Harrison, Stephen A., Vlad Ratziu, Quentin M. Anstee, et al.. (2023). Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 59(1). 51–63. 56 indexed citations
6.
Poynard, Thierry, Olivier Deckmyn, Valentina Peta, et al.. (2023). Prospective direct comparison of non‐invasive liver tests in outpatients with type 2 diabetes using intention‐to‐diagnose analysis. Alimentary Pharmacology & Therapeutics. 58(9). 888–902. 5 indexed citations
7.
Kumar, Divya P., Rebecca Caffrey, Jonathon Marioneaux, et al.. (2020). The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. Scientific Reports. 10(1). 9330–9330. 94 indexed citations
8.
Eddowes, Peter, M. Sasso, Michael Allison, et al.. (2019). Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 156(6). 1717–1730. 930 indexed citations breakdown →
9.
Ratziu, Vlad, Arun J. Sanyal, Rohit Loomba, et al.. (2019). REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemporary Clinical Trials. 84. 105803–105803. 106 indexed citations
10.
Bédossa, Pierre, Pierre‐Emmanuel Rautou, Philippe Bertheau, et al.. (2018). Utility and Safety of Liver Biopsy in Patients with Undetermined Liver Blood Test Anomalies after Allogeneic Hematopoietic Stem Cell Transplantation: A Monocentric Retrospective Cohort Study. Biology of Blood and Marrow Transplantation. 24(12). 2523–2531. 13 indexed citations
11.
Bédossa, Pierre. (2017). Pathology of non‐alcoholic fatty liver disease. Liver International. 37(S1). 85–89. 246 indexed citations
12.
Estrabaud, Emilie, Martine Lapalus, Philippe Broët, et al.. (2014). Reduction of MicroRNA 122 Expression in IFNL3 CT/TT Carriers and during Progression of Fibrosis in Patients with Chronic Hepatitis C. Journal of Virology. 88(11). 6394–6402. 29 indexed citations
13.
Bédossa, Pierre. (2013). Current histological classification of NAFLD: strength and limitations. Hepatology International. 7(S2). 765–770. 40 indexed citations
14.
Voisin, Thierry, Magali Fasseu, Christiane Rouyer‐Fessard, et al.. (2011). Aberrant Expression of OX1 Receptors for Orexins in Colon Cancers and Liver Metastases: an Openable Gate to Apoptosis. Cancer Research. 71(9). 3341–3351. 78 indexed citations
15.
Hammel, Pascal, Olivier Corcos, Olivier LaRochelle, et al.. (2009). Pancreatic Endocrine Microadenomatosis in Patients With von Hippel-Lindau Disease. The American Journal of Surgical Pathology. 33(5). 739–748. 38 indexed citations
16.
Hénégar, Corneliu, Joan Tordjman, Vincent Achard, et al.. (2008). Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome biology. 9(1). R14–R14. 345 indexed citations
17.
Asselah, Tarik, Ivan Bièche, Audrey Sabbagh, et al.. (2008). Gene expression and hepatitis C virus infection. Gut. 58(6). 846–858. 74 indexed citations
18.
Bédossa, Pierre. (2002). Mécanismes et cofacteurs de la fibrose au cours de l'infection virale C chronique. Gastroentérologie Clinique et Biologique. 26. 163–167. 1 indexed citations
19.
Taı̈eb, Julien, Laurent Castéra, Valérie Boige, et al.. (1998). [Hepatocellular carcinoma complicating agenesis of the portal vein].. PubMed. 22(2). 246–7. 8 indexed citations
20.
Houry, S, et al.. (1992). Cholangite sclérosante expérimentale secondaire à l'injection intra biliaire de formol chez le rat.. Chirurgie. 118(10).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zachary Goodman Breakdown of academic impact, for papers by Massimo Pinzani Breakdown of academic impact, for papers by David E. Kleiner Breakdown of academic impact, for papers by Michael Torbenson Breakdown of academic impact, for papers by Valérie Paradis Breakdown of academic impact, for papers by Frank Tacke Breakdown of academic impact, for papers by Linda D. Ferrell Breakdown of academic impact, for papers by Christian Trautwein Breakdown of academic impact, for papers by Alastair D. Burt Breakdown of academic impact, for papers by Frédéric Charlotte
Rankless by CCL
2026